Claims
Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.
KindShowingImportancePrizesTopicInflammation in atherosclerosis
The role of inflammatory processes in the initiation and progression of atherosclerosis and its clinical events, including biomarkers such as C-reactive protein and anti-inflammatory interventions (e.g., colchicine, IL-1 inhibitors) as evidence bearing on causality. Not for inflammation unrelated to atherosclerosis.
Chronic inflammation and insulin resistance are primary drivers of atherosclerosis independent of LDL
ContradictedThe evidence, examined directly, weighs against the claim.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Insulin resistanceAtherosclerotic cardiovascular diseaseLDL cholesterolimportance · notableImportance 0.50, from 0 to 1 · notable: a contested point in a live debate (also the default before judging). Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Lowering IL-6 or hsCRP-measured systemic inflammation reduces cardiovascular events regardless of the anti-inflammatory agent used
DoubtfulThe evidence weighs against the claim, but the examination is incomplete or the evidence is indirect.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular diseaseimportance · notableImportance 0.55, from 0 to 1 · notable: a contested point in a live debate (also the default before judging). Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
At least some anti-inflammatory therapies reduce cardiovascular events independently of lipid lowering
SupportedThe evidence favors the claim, but the examination is incomplete or the evidence is indirect.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Cardiovascular medicineAtherosclerotic cardiovascular diseaseimportance · majorImportance 0.65, from 0 to 1 · major: real consequence within a domain, actively argued. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
In the CANTOS trial, canakinumab reduced recurrent cardiovascular events without lowering LDL cholesterol
VerifiedThe evidence, examined directly, establishes the claim.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular diseaseCanakinumabLDL cholesterolimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trial
VerifiedThe evidence, examined directly, establishes the claim.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →ZiltivekimabAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Inflammation plays a causal role in atherosclerotic cardiovascular disease
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular diseaseimportance · minorImportance 0.40, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
In the CLEAR SYNERGY trial, colchicine did not reduce cardiovascular events after myocardial infarction
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →CLEAR SYNERGY trialColchicineAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
In the LoDoCo2 trial, low-dose colchicine reduced cardiovascular events in chronic coronary disease
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →LoDoCo2 trialColchicineAtherosclerotic cardiovascular diseaseimportance · minorImportance 0.25, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
In the COLCOT trial, low-dose colchicine reduced cardiovascular events after recent myocardial infarction
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Cardiovascular medicineColchicineCOLCOT trialimportance · minorImportance 0.25, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Low-dose methotrexate did not reduce cardiovascular events in the CIRT trial
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Atherosclerotic cardiovascular diseaseMethotrexateimportance · minorImportance 0.25, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →
Contribute
If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.